Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4475-4479

  Iwadate, Yasuo ^a   Matsutani, Tomoo ^a   Shinozaki, Natsuki ^a   Saeki, Naokatsu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

1p; 1p19q; ACNU; Chemotherapy; Glioma; Oligodendroglioma; PAV; Procarbazine; Vincristine

Indexed keywords

NIMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ANAPLASTIC OLIGODENDDROGLIAL TUMOR; ANAPLASTIC OLIGODENROGLIAL TUMOR; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19P; CHROMOSOME DELETION; CHROMOSOME DELETION 19P; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOMA; HUMAN; MALE; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE-FREE SURVIVAL; FEMALE; GENE DELETION; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NIMUSTINE; OLIGODENDROGLIOMA; PROCARBAZINE; PROSPECTIVE STUDIES; RADIOTHERAPY; VINCRISTINE;

EID: 84855183751     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Behin A, Hoang-Xuan K, Carpentier AF and Delattre JY: Primary brain tumors in adults. Lancet 361: 323-331, 2003.
2. Shaw EG, Scheithauser BW, O'Fallon JR, Tazelaar HD and Davis DH: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76: 428-434, 1992.
3. Celli P, Nofrone I, Palma L and Fortuna A: Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35: 1018-1034, 1994.
4. Leonardi MA and Lumenta CB: Oligodendrogliomas in CT/MR-era. Acta Neurochir 143: 1195-1203, 2001.
5. Lebrun C, Fontaine D, Ramaioli A, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, Michiels JF, Bourg V, Paquis P, Chatel M, Frenay M and Nice Brain Tumor Study Group: Long-term outcome of oligodendrogliomas. Neurology 62: 1783-1787, 2004.
6. Ozyigit G, Onal C, Gurkaynak M, Soylemezoglu F and Zorlu F: Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients. J Neurooncol 75: 189-193, 2005. (Pubitemid 41819724)
7. Douw L, Klein M, Fagel SS, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH, Beute GN, Sluimer JD, Slotman BJ, Reijneveld JC and Heimans JJ: Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8: 810-818, 2009.
8. Mason WP, Krol GS and DeAngelis LM: Low-grade oligodendrogliomas respond to chemotherapy. Neurology 46: 203-207, 1996.
9. Higuchi Y, Iwadate Y and Yamaura A. Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology 63: 2384-2386, 2004. (Pubitemid 40024356)
10. Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y and Saeki N: Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy. J Neurooncol 102: 443-449, 2011.
11. Sunyach MP, Jouvet A, Perol D, Jouanneau E, Guyotat J, Gignoux L, Carrie C and Frappaz D: Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol 85: 319-328, 2007. (Pubitemid 350147683)
12. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr. and National Cancer Institute of Canada Clinical Trial Group: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12: 2013-2021, 1994.
13. Van den Bent MJ, Kros JM, Heimans JJ, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ and Boogerd W: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 51: 1140-1145, 1998. (Pubitemid 28473415)
14. Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C and Mehta M: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neurooncol 11: 167-175, 2009.
15. Taliansky-Aronov A, Bokstein F, Lavon I and Siegal T: Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79: 153-157, 2006. (Pubitemid 44349943)
16. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsay DA, Nimer SD, DeAngelis LM and Cairncross JG: High-dose chemotherapy with stem cell rescue as an initial therapy for anaplastic oligodendroglioma: Long-term follow-up. Neurooncol 8: 183-188, 2006. (Pubitemid 46542663)
17. Paleologos NA, Macdonald DR, Vick NA and Cairncross JG: Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53: 1141-1143, 1999. (Pubitemid 29442142)
18. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG and Abrey LE: A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol 89: 187-193, 2008.
19. Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, Croteau D, Hasselbach L, Avedissian R and Schultz L: Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol 92: 57-63, 2009.
20. Gan HK, Rosenthal MA, Dowling A, Kalnins R, Algar E, Wong N, Benson A, Woods AM and Cher L: A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neurooncol 12: 500-507, 2010.
21. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M and Curran W: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplatic oligodendroglioma. J Clin Oncol 24: 2707-2714, 2006.
22. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D and Gorlia T: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplatic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715-2722, 2006. (Pubitemid 46630567)
23. Kanner AA, Staugaitis SM, Castilla EA, Chemova O, Prayson RA, Vogelbaum MA, Stevens G, Peereboom D, Suh J, Lee SY, Tubbs RR and Barnett GH: The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 104: 542-550, 2006.
24. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ and Aldape K: Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18: 360-369, 2008. (Pubitemid 351782844)
25. Gadji M, Fortin D, Tsanaclis AM and Drouin R: Is 1p/19q deletion a diagnostic marker of oligodendrogliomas? Cancer Genet Cytogenet 194: 12-22, 2009.
26. Bromberg JEC and van den Bent MJ: Oligodendrogliomas: molecular biology and treatment. Oncologist 14: 155-163, 2009.
27. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG and Buckner JC: A t(1; 19)(q10; p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodedroglioma. Cancer Res 66: 9852-9861, 2006. (Pubitemid 44672036)
28. Ty AU, See SJ, Rao JP, Khoo JB and Wong MC: Oliogdendroglial tumor chemotherapy using decreased-dose intensity PCV: a Singapore experience. Neurology 66: 247-249, 2006. (Pubitemid 43970164)